Bicara Therapeutics Inc. Operating Income
Bicara Therapeutics Inc. (BCAX) reported Operating Income of -$59.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Bicara Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$59.95M.
- Bicara Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$60.24M.
- Bicara Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$41.12M.
- Bicara Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$40.68M.
- Bicara Therapeutics Inc. operating income (loss) for fiscal 2025 was -$155.60M.
- Bicara Therapeutics Inc. operating income (loss) for fiscal 2024 was -$82.39M.
- Bicara Therapeutics Inc. operating income (loss) for fiscal 2023 was -$39.89M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$59.95M 10-Q · filed 2026-08-11 | -$120.19M 10-Q · filed 2026-08-11 | -$161.31M derived: sum of 3 quarters · filed 2026-08-11 | -$201.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$60.24M 10-Q · filed 2026-05-11 | -$101.36M derived: sum of 2 quarters · filed 2026-05-11 | -$142.04M derived: sum of 3 quarters · filed 2026-05-11 | -$174.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$81.80M derived: sum of 2 quarters · filed 2026-03-30 | -$113.82M derived: sum of 3 quarters · filed 2026-08-11 | -$155.60M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$40.68M 10-Q · filed 2025-11-10 | -$72.69M derived: sum of 2 quarters · filed 2026-08-11 | -$114.48M 10-Q · filed 2025-11-10 | -$141.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$32.02M 10-Q · filed 2026-08-11 | -$73.81M 10-Q · filed 2026-08-11 | -$100.44M derived: sum of 3 quarters · filed 2026-08-11 | -$121.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$41.79M 10-Q · filed 2026-05-11 | -$68.42M derived: sum of 2 quarters · filed 2026-05-11 | -$89.05M derived: sum of 3 quarters · filed 2026-05-11 | -$108.80M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$26.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$47.27M derived: sum of 2 quarters · filed 2026-03-30 | -$67.02M derived: sum of 3 quarters · filed 2026-03-30 | -$82.39M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$20.63M 10-Q · filed 2025-11-10 | -$40.38M derived: sum of 2 quarters · filed 2025-11-10 | -$55.75M 10-Q · filed 2025-11-10 | -$69.44M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$19.75M 10-Q · filed 2025-08-12 | -$35.12M 10-Q · filed 2025-08-12 | -$48.81M derived: sum of 3 quarters · filed 2025-08-12 | -$58.34M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$15.37M 10-Q · filed 2025-05-13 | -$29.06M derived: sum of 2 quarters · filed 2025-05-13 | -$38.59M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$13.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$23.22M derived: sum of 2 quarters · filed 2025-03-27 | -$39.89M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$9.53M 10-Q · filed 2024-11-12 | -$26.20M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |